Overview

FRIDA

A randomized, double-blind, placebo-controlled Phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer

Objective

Evaluate progression-free survival in patients with metastatic triple-negative breast cancer treated with the combination of paclitaxel and oral reparixin compared to paclitaxel alone.

Principal Investigator(s)

Jason Comer, MD

Clinical Trial Categories

Oncology

Contact

Stephanie Porenta: 425.467.3986, Stephanie.Porenta@overlakehospital.org

Complete the online contact information form.

Learn More
Location

Overlake Medical Center

1035 116th Ave. NE 
Bellevue, WA 98004
Main: 425.688.5000

Find locations + directions

Find locations + directions

Contact us

Contact us

View all classes + events

View all classes + events